892 related articles for article (PubMed ID: 9023558)
1. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
3. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.
Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S
Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
5. Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters.
Soyer HP
J Cutan Pathol; 1991 Aug; 18(4):264-72. PubMed ID: 1719049
[TBL] [Abstract][Full Text] [Related]
6. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin.
Talve LA; Collan YU; Ekfors TO
J Cutan Pathol; 1996 Aug; 23(4):335-43. PubMed ID: 8864921
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
Weiss J; Heine M; Körner B; Pilch H; Jung EG
Br J Dermatol; 1995 Jul; 133(1):23-31. PubMed ID: 7669636
[TBL] [Abstract][Full Text] [Related]
8. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions.
Korabiowska M; Brinck U; Mirecka J; Kellner S; Marx D; Schauer A
In Vivo; 1995; 9(5):433-8. PubMed ID: 8900920
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of biomarkers in malignant melanoma.
Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
[TBL] [Abstract][Full Text] [Related]
10. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical profile of oral mucosal and head and neck cutaneous melanoma.
Alaeddini M; Etemad-Moghadam S
J Oral Pathol Med; 2015 Mar; 44(3):234-8. PubMed ID: 25048051
[TBL] [Abstract][Full Text] [Related]
13. Expression of the p53 protein in malignant melanomas as a prognostic indicator.
Yamamoto M; Takahashi H; Saitoh K; Horikoshi T; Takahashi M
Arch Dermatol Res; 1995; 287(2):146-51. PubMed ID: 7763085
[TBL] [Abstract][Full Text] [Related]
14. The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma.
Kaufmann C; Kempf W; Mangana J; Cheng P; Emberger M; Lang R; Kaiser AK; Lattmann E; Levesque M; Dummer R; Koelblinger P
Histopathology; 2020 Sep; 77(3):460-470. PubMed ID: 32374893
[TBL] [Abstract][Full Text] [Related]
15. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors.
Sparrow LE; English DR; Taran JM; Heenan PJ
Am J Dermatopathol; 1998 Feb; 20(1):12-6. PubMed ID: 9504663
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation markers in predicting metastases in malignant melanoma.
Reddy VB; Gattuso P; Aranha G; Carson HJ
J Cutan Pathol; 1995 Jun; 22(3):248-51. PubMed ID: 7593819
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
Ramsay JA; From L; Iscoe NA; Kahn HJ
J Invest Dermatol; 1995 Jul; 105(1):22-6. PubMed ID: 7615970
[TBL] [Abstract][Full Text] [Related]
19. Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging.
Robinson EM; Rosenbaum BE; Zhang Y; Rogers R; Tchack J; Berman RS; Darvishian F; Osman I; Shapiro RL; Shao Y; Polsky D
J Surg Oncol; 2018 Jul; 118(1):150-156. PubMed ID: 29878361
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53 over-expression in thin melanomas.
Sparrow LE; English DR; Heenan PJ; Dawkins HJ; Taran J
Melanoma Res; 1995 Dec; 5(6):387-92. PubMed ID: 8589612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]